AVP-786 is primarily used in the treatment of central nervous system disorders, particularly for managing agitation in patients with Alzheimer's disease. It combines two active components that work synergistically to modulate neurotransmitter activity, helping to reduce symptoms such as aggression, irritability, and emotional distress. This makes it a valuable option for improving the quality of life for both patients and caregivers. Additionally, AVP-786 is being investigated for its potential in addressing other neurological and psychiatric conditions, such as major depressive disorder and traumatic brain injury, due to its unique mechanism of action. Its application is closely monitored in clinical settings to ensure optimal dosing and minimize side effects.